

## Supplemental Table of Contents

Supplemental Table 1A. HD patient characteristics, by gout indications

Supplemental Table 1B. PD patient characteristics, by gout indications

Supplemental Table 2. Patient characteristics in HD and PD patients, with and without gout, after propensity score matching.

**Supplemental Figure 1.** Association between 5-category gout exposure and all-cause mortality in HD (A) and PD (B).

Supplemental Table 1A. HD patient characteristics, by gout indications

	HD				
	colchicine Rx 1145	febuxostat Rx 517	allopurinol Rx 6380	prior gout diagnosis 1367	none 60888
<b>Demographics</b>					
Patient age, years	67.0(13.1)	68.8(13.1)	70.0(12.4)	66.7(13.7)	63.2(14.9)
Male, %	67%	62%	64%	63%	55%
Black race, %	43%	26%	32%	45%	39%
Body mass index, kg/m <sup>2</sup>	30.3(7.3)	29.7(7.2)	30.3(7.3)	29.0(7.1)	28.3(7.1)
Time on dialysis, years	2.25(2.96)	1.49(2.05)	1.98(2.58)	3.88(4.14)	3.35(4.04)
<b>Comorbidity history</b>					
Coronary artery disease	28%	25%	25%	34%	19%
Cancer (non-skin)	8%	7%	8%	11%	5%
Other cardiovascular disease	24%	26%	26%	30%	16%
Cerebrovascular disease	7%	6%	7%	10%	6%
Congestive heart failure	32%	31%	32%	34%	24%
Diabetes	61%	61%	65%	64%	66%
Gastrointestinal bleeding	3%	4%	4%	9%	4%
Hypertension	83%	83%	82%	93%	79%
Lung disease	11%	10%	11%	13%	7%
Neurologic disease	5%	5%	5%	11%	5%
Psychiatric disorder	21%	25%	25%	30%	24%
Peripheral vascular disease	13%	13%	13%	19%	12%
Recurrent cellulitis/gangrene	5%	3%	4%	9%	5%

Dialysis treatments					
Vascular access type					
Catheter	33%	40%	39%	32%	41%
Fistula	54%	46%	50%	54%	47%
Graft	12%	13%	11%	13%	13%
Singlepool Kt/V	1.53(0.28)	1.53(0.28)	1.52(0.29)	1.57(0.26)	1.54(0.28)
Labs					
Phosphorus, mg/dL	5.17(1.57)	5.20(1.58)	5.00(1.45)	5.17(1.54)	5.19(1.64)
Albumin, g/dL	3.67(0.47)	3.64(0.46)	3.64(0.45)	3.68(0.48)	3.63(0.49)
Uric acid, mg/dL	5.89(1.83)	4.70(1.71)	5.40(1.55)	6.21(1.32)	5.94(1.45)
PTH, pg/mL	330[202,538]	295[168,456]	301[180,476]	363[225,628]	322[188,535]
Creatinine, mg/dL	7.43(2.90)	6.88(2.76)	6.85(2.80)	8.11(3.13)	7.57(3.07)
Hemoglobin, g/dL	10.6(1.4)	10.5(1.3)	10.6(1.4)	10.6(1.4)	10.5(1.4)
Ferritin, ng/mL	571[298,937]	609[312,874]	593[323,932]	681[392,1004]	615[338,948]
White blood cell count, 10 <sup>3</sup> cells/mm <sup>3</sup>	6.7[5.2,8.3]	6.9[5.4,8.4]	6.9[5.5,8.5]	6.5[5.1,8.1]	6.7[5.4,8.4]

Mean (std dev), median [inter-quartile range], or % shown. Mutually exclusive categories were defined hierarchically as (1) colchicine Rx alone; (2) febuxostat Rx with no colchicine Rx; (3) allopurinol Rx with no colchicine or febuxostat Rx; (4) prior diagnosis of gout with no colchicine, febuxostat, or allopurinol Rx; and (5) none of the above.

Supplemental Table 1B. PD patient characteristics, by gout indications

	PD				
	colchicine Rx 142	febuxostat Rx 73	allopurinol Rx 601	prior gout diagnosis 244	none 4057
<b>Demographics</b>					
Patient age, years	61.6(13.6)	63.2(13.1)	62.8(13.7)	62.4(13.9)	56.2(15.3)
Male, %	62%	75%	72%	63%	53%
Black race, %	31%	16%	25%	25%	27%
Body mass index, kg/m <sup>2</sup>	30.9(6.5)	30.8(7.2)	30.3(6.0)	29.9(6.1)	29.0(6.5)
Time on dialysis, years	2.06(2.72)	1.32(1.62)	2.14(2.95)	2.71(2.79)	2.63(3.39)
<b>Comorbidity history</b>					
Coronary artery disease	21%	37%	22%	31%	18%
Cancer (non-skin)	9%	9%	9%	13%	5%
Other cardiovascular disease	11%	27%	14%	17%	10%
Cerebrovascular disease	5%	7%	5%	9%	4%
Congestive heart failure	14%	26%	13%	22%	12%
Diabetes	47%	49%	50%	44%	52%
Gastrointestinal bleeding	0%	1%	3%	5%	1%
Hypertension	78%	85%	76%	85%	75%
Lung disease	6%	11%	4%	10%	4%
Neurologic disease	1%	4%	2%	4%	2%
Psychiatric disorder	14%	16%	18%	25%	19%
Peripheral vascular disease	11%	16%	8%	11%	9%
Recurrent cellulitis/gangrene	1%	2%	2%	4%	2%
<b>Labs</b>					
Phosphorus, mg/dL	5.06(1.51)	5.06(1.23)	5.02(1.40)	5.25(1.55)	5.31(1.56)
Albumin, g/dL	3.55(0.44)	3.53(0.41)	3.55(0.44)	3.53(0.41)	3.51(0.47)
Uric acid, mg/dL	6.26(1.56)	5.46(1.71)	5.99(2.16)	6.60(1.85)	6.66(1.62)
PTH, pg/mL	352[213,542]	309[203,460]	344[202,516]	367[221,545]	358[210,556]
Creatinine, mg/dL	8.53(3.64)	6.93(3.51)	8.53(4.13)	9.42(4.42)	9.04(4.30)

Hemoglobin, g/dL	11.0(1.5)	11.5(1.5)	11.2(1.6)	11.0(1.4)	11.0(1.5)
Ferritin, ng/mL	491[256,880]	539[260,902]	514[260,921]	660[352,996]	582[300,933]
White blood cell count, 10 <sup>3</sup> cells/mm <sup>3</sup>	6.9[5.7,9.0]	7.7[5.6,9.2]	7.3[5.7,9.2]	7.5[5.9,9.3]	7.2[5.7,9.2]


Mean (std dev), median [inter-quartile range], or % shown. Mutually exclusive categories were defined hierarchically as (1) colchicine Rx alone; (2) febuxostat Rx with no colchicine Rx; (3) allopurinol Rx with no colchicine or febuxostat Rx; (4) prior diagnosis of gout with no colchicine, febuxostat, or allopurinol Rx; and (5) none of the above.

Supplemental Table 2. Patient characteristics in HD and PD patients, with and without gout, after propensity score matching.

	HD		PD	
	No gout 9409	Gout 9409	No gout 1060	Gout 1060
<b>Demographics</b>				
Patient age, years	69.2(12.9)	69.1(12.8)	62.7(13.8)	62.6(13.7)
Male, %	64%	64%	69%	69%
Black race, %	34%	35%	24%	25%
Body mass index, kg/m <sup>2</sup>	30.0(7.6)	30.0(7.3)	30.3(6.6)	30.3(6.2)
Time on dialysis, years	2.34(2.84)	2.27(2.97)	2.20(2.54)	2.20(2.83)
<b>Comorbidity history</b>				
Coronary artery disease	27%	26%	24%	25%
Cancer (non-skin)	9%	9%	10%	10%
Other cardiovascular disease	26%	26%	14%	15%
Cerebrovascular disease	7%	7%	7%	6%
Congestive heart failure	32%	32%	14%	16%
Diabetes	64%	64%	47%	48%
Gastrointestinal bleeding	4%	4%	3%	3%
Hypertension	83%	83%	79%	79%
Lung disease	11%	11%	7%	6%
Neurologic disease	6%	6%	3%	3%
Psychiatric disorder	25%	25%	18%	19%
Peripheral vascular disease	14%	14%	10%	10%
Recurrent cellulitis/gangrene	5%	5%	2%	2%
<b>Dialysis treatments</b>				
<b>Vascular access type</b>				
Catheter	38%	37%		
Fistula	51%	51%		
Graft	12%	12%		
Singlepool Kt/V	1.52(0.27)	1.53(0.28)		
<b>Labs</b>				
Phosphorus, mg/dL	5.04(1.55)	5.06(1.49)	5.08(1.41)	5.08(1.44)
Albumin, g/dL	3.65(0.46)	3.65(0.46)	3.53(0.45)	3.54(0.43)
Uric acid, mg/dL	5.84(1.37)	5.53(1.63)	6.72(1.77)	6.14(1.95)
PTH, pg/mL	297[180,481]	312[187,500]	335[193,521]	346[206,520]
Creatinine, mg/dL	7.08(2.86)	7.11(2.90)	8.70(4.11)	8.62(4.14)
Hemoglobin, g/dL	10.6(1.3)	10.6(1.4)	11.1(1.6)	11.1(1.5)
Ferritin, ng/mL	583[319,916]	603[328,941]	578[302,930]	549[271,939]
White blood cell count, 10 <sup>3</sup> cells/mm <sup>3</sup>	6.8[5.5,8.4]	6.8[5.4,8.5]	7.2[5.8,9.2]	7.3[5.7,9.3]

Gout: active Rx for colchicine or feboxustat or allopurinol; or prior diagnosis of gout (Gout3);  
Mean (std dev), median [inter-quartile range], or % shown.

**Supplemental Figure1.** Association between 5-category gout exposure and all-cause mortality in HD (A) and PD (B).



Note: Mutually exclusive categories were defined hierarchically as (1) colchicine Rx alone; (2) febuxostat Rx with no colchicine Rx; (3) allopurinol Rx with no colchicine or febuxostat Rx; (4)

prior diagnosis of gout with no colchicine, febuxostat, or allopurinol Rx; and (5) none of the above. Cox models were stratified by study phase and EHR data source, and fitted with progressive covariate adjustments: Model 1: unadjusted; Model 2: age only; Model 3: Model 2 + other demographics, including sex, Black race, BMI, and dialysis vintage; Model 4: Model 3 + 13 comorbidities; Model 5: Model 4 adjustments + albumin, creatinine, and phosphorus; Model 6 (HD only): Model 5 adjustments + vascular access type.